Manuals+

Novo Nordisk Financial Report: H1 2025 Highlights

An overview of Novo Nordisk's financial performance for the first half of 2025.

Key Financial Performance

Novo Nordisk reported a significant increase in sales for the first six months of 2025. Sales grew by 16% in Danish kroner and 18% at constant exchange rates, reaching DKK 154.9 billion. Operating profit also saw a substantial rise of 25% in Danish kroner and 29% at constant exchange rates, totaling DKK 72.2 billion.

Segment Performance

The report details strong performance across key therapeutic areas. Diabetes and Obesity care sales increased by 16% (18% at CER), largely driven by a 56% growth in Obesity care sales. Rare disease sales also grew by 14% (15% at CER).

Strategic Outlook

Novo Nordisk has updated its financial outlook for 2025, expecting sales growth between 8-14% at CER and operating profit growth between 10-16% at CER. The company continues to focus on innovation and expanding access to its treatments globally.

About Novo Nordisk

Novo Nordisk is a global healthcare company with a long-standing heritage in diabetes care. The company is dedicated to driving change to defeat serious chronic diseases through scientific breakthroughs and expanded access to medicines. Learn more at novonordisk.com.

PDF preview unavailable. Download the PDF instead.

CA250806-Q2-Earnings Wdesk Fidelity Content Translations Version 014.002.092 Workiva

Related Documents

Preview Novo Nordisk Investor Presentation H1 2025: Financials and Strategic Update
Novo Nordisk's investor presentation for the first six months of 2025, detailing financial performance, strategic aspirations, pipeline advancements in diabetes, obesity, rare diseases, and cardiovascular/emerging therapies, alongside market insights and sustainability efforts.
Preview Novo Nordisk Investor Presentation: First Six Months of 2025
An investor presentation from Novo Nordisk detailing their performance and strategic aspirations for the first six months of 2025. The report covers progress on environmental, social, and governance (ESG) goals, commercial execution in diabetes and obesity care, innovation in therapeutic focus, and financial highlights.
Preview Novo Nordisk R&D Investor Event: Diabetes and Obesity Care Focus
Presentation from Novo Nordisk's R&D Investor Event on June 22, 2025, in Chicago. The event focuses on the company's advancements and strategies in diabetes and obesity care, highlighting key research, clinical trials, and future outlook.
Preview Novo Nordisk R&D Investor Event: Diabetes and Obesity Care Focus
Presentation from Novo Nordisk's R&D Investor event held on June 22, 2025, in Chicago. The event highlights the company's focus on diabetes and obesity care, detailing research, clinical trials, and strategic aspirations.
Preview FlexPro PenMate User Manual - Easy Injection Guide
A comprehensive user manual for the FlexPro PenMate, detailing activation, injection, pen replacement, and care instructions for Norditropin FlexPro and Sogroya pens. Learn how to use the PenMate for accurate and safe growth hormone injections.
Preview Návod k použití FlexPro® PenMate® a injekčních per Norditropin® FlexPro® a Sogroya®
Podrobný návod k použití pomůcky FlexPro® PenMate® pro aplikaci růstového hormonu s pery Norditropin® FlexPro® a Sogroya®. Zahrnuje přípravu, nastavení dávky, aplikaci a údržbu.
Preview FlexPro® PenMate®: Istruzioni per l'uso e Guida alla Somministrazione
Guida completa e dettagliata per l'utilizzo di FlexPro® PenMate®, un accessorio innovativo per migliorare l'esperienza di iniezione con le penne per ormone della crescita Norditropin® FlexPro® e Sogroya®. Scopri come preparare, selezionare la dose, iniettare e conservare correttamente il tuo dispositivo per una terapia efficace e sicura.
Preview Handleiding FlexPro® PenMate®: Gebruik en Onderhoud
Gedetailleerde instructies voor het gebruik van de Novo Nordisk FlexPro® PenMate® met Norditropin® FlexPro® en Sogroya® groeihormoonpennen. Leer hoe u de PenMate® klaarmaakt, doseert, injecteert en onderhoudt.